


05-04-05

EFW/635  
AP 3Practitioner's Docket No. MPI00-459P1RM (formerly 10147-56U1)**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Meyers, Rachel E., et al.		
Application No.:	10/001,851	Group No.:	1635
Filed:	November 20, 2001	Examiner:	Schultz, James
For:	47169 AND 33935, NOVEL HUMAN GLYCOSYL TRANSFERASES AND USES THEREFOR		

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**TRANSMITTAL**

1. Transmitted herewith for this application is/are:

- a. This Transmittal (2 pages);
- b. Petition for Extension of Time (2 pages – in duplicate);
- c. Authorization to Act in a Representative Capacity (2 pages);
- d. Statement of Limited Recognition under 37 CFR §11.9(b) for Mario Cloutier (1 page); and
- e. Return Postcard.

**STATUS**

2. Applicant is other than a small entity.

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

with sufficient postage as first class mail.

**37 C.F.R. SECTION 1.10\***

as "Express Mail Post Office to Addressee"  
 Mailing Label No. EV528716749US

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

Signature

Carolyn Willey

Carolyn Willey  
 (type or print name of person certifying)

Date: May 3, 2005

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI00-459P1RM (formerly 10147-56U1)**

**FEE DEFICIENCY**


3. If any additional extension and/or fee is required, charge Account No. 501668.  
If any additional fee for claims is required, charge Account No. 501668.

May 3, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By Mario Cloutier  
Mario Cloutier

Limited Recognition Under 37 C.F.R. §11.9(b)  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-577-3522  
Facsimile - 617-551-8820



Practitioner's Docket No. **MPI00-459P1RM**

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:	Rachel E. Meyers, et al.		
Application No.:	10/001,851	Group No.:	1635
Filed:	November 20, 2001	Examiner:	Schultz, James
For:	47169 AND 33935, NOVEL HUMAN GLYCOSYL TRANSFERASES AND USES THEREFOR		

**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**AUTHORIZATION TO ACT IN A REPRESENTATIVE CAPACITY**

Dear Sir:

The practitioner named below is authorized to conduct interviews and has the authority to bind the principal concerned. Furthermore, the practitioner is authorized to file correspondence in the above-identified application pursuant to 37 CFR 1.34:

Mario Cloutier  
Limited Recognition Under 37 CFR §11.9(b)  
Customer Number 30405 or  
Millennium Pharmaceuticals, Inc.  
40 Landsdowne Street  
Cambridge, MA 02139

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No. EV528716749US

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

Signature

Carolyn Willey

(type or print name of person certifying)

Date: May 3, 2005

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI00-459P1RM**

**This is not a Power of Attorney to the above-named practitioner.**

Accordingly, the practitioner named above does **not** have authority to sign a request to change the correspondence address, a request for an express abandonment, a disclaimer, a power of attorney, or other document requiring the signature of the applicant, assignee of the entire interest or an attorney of record. If appropriate, a separate Power of Attorney to the above-named practitioner should be executed and filed in the United States Patent and Trademark Office.

Please continue to forward all written and telephonic communications to Tracy M. Sioussat at the address and telephone number listed below.

**SIGNATURE of Practitioner of Record**

Respectfully submitted,

May 3, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By *Tracy M. Sioussat*  
Tracy M. Sioussat  
Attorney/Agent for Applicant  
Reg. No. 50,609  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone: (617) 374-7679  
Facsimile - (617) 551-8820



**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATE PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)**

Mario Cloutier is hereby given limited recognition under 37 CFR 11.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

**Expires: December 29, 2006**

  
\_\_\_\_\_  
**Harry I. Moatz**  
Director of Enrollment and Discipline